

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Duality Biotherapeutics, Inc.**

**映恩生物**

*(Incorporated under the laws of the Cayman Islands with limited liability)*

**(Stock code: 9606)**

### **ANNOUNCEMENT MADE PURSUANT TO RULE 13.10 OF THE LISTING RULES**

This announcement is made at the request of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and pursuant to Rule 13.10 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”).

The board (the “**Board**”) of directors of Duality Biotherapeutics, Inc. (the “**Company**”) has noted the recent fluctuation in the trading price and trading volume of the shares of the Company (the “**Shares**”) on the Stock Exchange on June 9, 2025 and June 10, 2025. The Board has also noted that the Company published a press article on its website relating to preliminary data of the Company’s ADC candidates orally presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (<https://en.dualitybiologics.com/news/590.html>) (the “**Press Article**”) on June 5, 2025.

Having made such enquiry with respect to the Company as is reasonable in the circumstances, the Board confirms that (i) the information contained in the Press Article does not constitute inside information for the purpose of Rule 13.09(2) of the Listing Rules or the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong); (ii) it is not aware of any reason for the fluctuation in the trading price and trading volume of the Shares or of any information which must be announced to avoid a false market in the Company’s securities or of any inside information that needs to be disclosed; and (iii) the operations of the Company remain normal.

Shareholders of the Company and prospective investors are advised to exercise caution when dealing in the securities of the Company.

This announcement is made by the order of the Company. The Board collectively and individually accepts responsibility for the accuracy of this announcement.

By order of the Board  
**Duality Biotherapeutics, Inc.**  
**Dr. ZHU Zhongyuan**  
*Chairman of the Board, Executive Director  
and Chief Executive Officer*

Hong Kong, June 10, 2025

*As at the date of this announcement, the board of directors of the Company comprises (i) Dr. ZHU Zhongyuan, Mr. ZHANG Shaoren and Ms. SI Wen as executive directors; (ii) Mr. CAI Zhiyang and Dr. YU Tao as non-executive directors; and (iii) Mr. XIE Dong, Mr. GAO Fengyong and Ms. CHUAI Shuyin as independent non-executive directors.*